Puma BiotechnologyNASDAQ: PBYI

Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2024 Earnings Call August 1, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chief Executive Officer, President and Chairman Maximo Nougues - Chief Financial Officer Jeff Ludwig - Chief Commercial Officer Conference Call Participants Marc Frahm - TD Cowen Ed White - H.C. Wainwright Operator Good afternoon.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that two abstracts for its drug Alisertib to be presented at the 2024 ASCO Annual Meeting are now posted on ASCO.org.

Puma Biotechnology (PBYI) announces a smaller-than-anticipated loss in the first quarter of 2024. The company is sticking to its revenue forecast for the year.

Puma Biotechnology, Inc. (NASDAQ:PBYI) will be hosting its Q1 2024 Earnings Conference Call on May 2, 2024 at 4:30 PM ET. Present at the call will be Mariann Ohanesian, Alan Auerbach, Jeff Ludwig, and Maximo Nougues. Participants include Ed White from H.C. Wainwright and Divya Rao from TD Cowen. The operator greets everyone with a good afternoon.

Puma Biotech (PBYI) reported a quarterly loss of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.16. This is compared to earnings of $0.09 per share in the same quarter last year.

During Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors are expected to pay close attention to the sales of its only cancer drug on the market, Nerlynx.